Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 10;8(1):69.
doi: 10.3390/jcm8010069.

Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)-Current Considerations for Clinical Practice

Frederik Trinkmann  1 , Joachim Saur  2 , Martin Borggrefe  3   4 , Ibrahim Akin  5   6
Affiliations
Review

Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)-Current Considerations for Clinical Practice

Frederik Trinkmann et al. J Clin Med. .

Abstract

In patients with chronic obstructive pulmonary disease (COPD), cardiovascular comorbidities are highly prevalent and associated with considerable morbidity and mortality. This coincidence is increasingly seen in context of a "cardiopulmonary continuum" rather than being simply attributed to shared risk factors such as cigarette smoking. Overlapping symptoms such as dyspnea or chest pain lead to a worse prognosis due to missed concomitant diagnoses. Moreover, medication is often withheld as a result of unfounded concerns about side effects. Despite the frequent coincidence, current guidelines are still mostly restricted to the management of the individual disease. Future diagnostic and therapeutic strategies should therefore be guided by an integrative perspective as well as a refined phenotyping of disease entities.

Keywords: COPD; cardiovascular; comorbidities; diagnostics; therapy.

PubMed Disclaimer

Conflict of interest statement

Frederik Trinkmann received travel support from Actelion, Boehringer Ingelheim, Chiesi, Novartis, Mundipharma, and TEVA as well as speaker/consultation fees from Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Roche, and Novartis. Joachim Saur received travel support and speaker fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche. Martin Borggrefe received speaker/consultation fees from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Impulse Dynamics, and Zoll Medical. Ibrahim Akin received travel support as well as speaker/consultation fees Abiomed, Bayer, Boehringer Ingelheim, and St. Jude Medical.

Figures

Figure 1
Figure 1
Cardiovascular and pulmonary disease in the context of inflammation (“cardiopulmonary continuum”, modified after [1,4]).
See this image and copyright information in PMC

References

    1. Ukena C., Mahfoud F., Kindermann M., Kindermann I., Bals R., Voors A.A., van Veldhuisen D.J., Bohm M. The cardiopulmonary continuum systemic inflammation as ‘common soil’ of heart and lung disease. Int. J. Cardiol. 2010;145:172–176. doi: 10.1016/j.ijcard.2010.04.082. - DOI - PubMed
    1. Brown J.P., Martinez C.H. Chronic obstructive pulmonary disease comorbidities. Curr. Opin. Pulm. Med. 2016;22:113–118. doi: 10.1097/MCP.0000000000000241. - DOI - PubMed
    1. Camiciottoli G., Bigazzi F., Magni C., Bonti V., Diciotti S., Bartolucci M., Mascalchi M., Pistolesi M. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int. J. Chronic Obstruct. Pulm. Dis. 2016;11:2229–2236. doi: 10.2147/COPD.S111724. - DOI - PMC - PubMed
    1. Boschetto P., Beghe B., Fabbri L.M., Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice. Respirology. 2012;17:422–431. doi: 10.1111/j.1440-1843.2011.02118.x. - DOI - PubMed
    1. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128:2640–2646. doi: 10.1378/chest.128.4.2640. - DOI - PubMed

LinkOut - more resources